Laboratory of Cancer Biology in State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, P, R, China.
Mol Cancer. 2010 Nov 29;9:307. doi: 10.1186/1476-4598-9-307.
Activation of the RON receptor tyrosine kinase, a member of the c-MET family, regulates tumorigenic phenotypes. The RON extracellular domains are critical in regulating these activities. The objective of this study was to determine the role of the first IPT domain in regulating RON-mediated tumorigenic activities and the underlying mechanisms.
Two RON variants, RON160 and RONE5/6in with deletion and insertion in the first IPT domain, respectively, were molecularly cloned. RON160 was a splicing variant generated by deletion of 109 amino acids encoded by exons 5 and 6. In contrast, RONE5/6in was derived from a transcript with an insertion of 20 amino acids between exons 5 and 6. Both RON160 and RONE5/6in were proteolytically matured into two-chain receptor and expressed on the cell surface. RON160 was constitutively active with tyrosine phosphorylation. However, activation of RONE5/6in required ligand stimulation. Deletion resulted in the resistance of RON160 to proteolytic digestion by cell associated trypsin-like enzymes. RON160 also resisted anti-RON antibody-induced receptor internalization. These features contributed to sustained intracellular signaling cascades. On the other hand, RONE5/6in was highly susceptible to protease digestion, which led to formation of a truncated variant known as RONp110. RONE5/6in also underwent rapid internalization upon anti-RON antibody treatment, which led to signaling attenuation. Although ligand-induced activation of RONE5/6in partially caused epithelial to mesenchymal transition (EMT), it was RON160 that showed cell-transforming activities in cell focus formation and anchorage-independent growth. RON160-mediated EMT is also associated with increased motile/invasive activity.
Alterations in the first IPT domain in extracellular region differentially regulate RON mediated tumorigenic activities. Deletion of the first IPT results in formation of oncogenic variant RON160. Enhanced degradation and internalization with attenuated signaling cascades could be the mechanisms underlying non-tumorigenic features of RONE5/6in.
RON 受体酪氨酸激酶的激活,是 c-MET 家族的一员,调节肿瘤发生表型。RON 的细胞外结构域在调节这些活性中起着关键作用。本研究的目的是确定第一个 IPT 结构域在调节 RON 介导的肿瘤发生活性中的作用及其潜在机制。
两种 RON 变体,RON160 和 RONE5/6in,分别在第一个 IPT 结构域缺失和插入,通过分子克隆进行了克隆。RON160 是通过外显子 5 和 6 编码的 109 个氨基酸缺失而产生的剪接变体。相比之下,RONONE5/6in 是由外显子 5 和 6 之间插入 20 个氨基酸的转录物产生的。RON160 和 RONE5/6in 均被蛋白水解成熟为二聚体受体,并表达在细胞表面。RON160 是组成性激活的,酪氨酸磷酸化。然而,RONONE5/6in 的激活需要配体刺激。缺失导致 RON160 抵抗细胞相关胰蛋白酶样酶的蛋白水解消化。RON160 也抵抗抗 RON 抗体诱导的受体内化。这些特征促成了持续的细胞内信号级联反应。另一方面,RONONE5/6in 非常容易被蛋白酶消化,这导致形成一种称为 RONp110 的截断变体。RONONE5/6in 在抗 RON 抗体处理后也迅速内化,导致信号衰减。尽管配体诱导的 RONE5/6in 激活部分导致上皮间质转化(EMT),但 RON160 在细胞焦点形成和锚定非依赖性生长中表现出细胞转化活性。RON160 介导的 EMT 也与运动/侵袭活性增加有关。
细胞外区第一个 IPT 结构域的改变差异调节 RON 介导的肿瘤发生活性。第一个 IPT 的缺失导致致癌变体 RON160 的形成。增强的降解和内化以及减弱的信号级联反应可能是 RONE5/6in 非肿瘤发生特征的机制。